Kalaris Therapeutics, Inc. Common Stock KLRS Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$10.86M-8.6% | -$10M+15.9% | -$11.89M-4.8% | -$11.35M-11.3% | -$10.2M+53.7% | ||
| $10K0.0% | $10K— | —— | —— | —— | ||
| $580K+74.2% | $333K-47.8% | $638K+8.0% | $591K+58.0% | $374K+33.6% | ||
| -$11.58M-64.1% | -$7.06M+37.7% | -$11.33M+9.6% | -$12.54M-68.5% | -$7.44M+5.2% | ||
| -$50.35M-921% | -$4.93M0.0% | -$4.93M0.0% | -$4.93M0.0% | -$4.93M-199% | ||
| -$1.7M-104% | $47.74M— | —— | —— | $107.27M+1,316% | ||
| -$63.63M-214% | $55.67M— | —— | —— | $99.83M+36,533% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Kalaris Therapeutics, Inc. Common Stock generate?
- Kalaris Therapeutics, Inc. Common Stock (KLRS) generated -$42.5M in operating cash flow over the trailing twelve months.
- What is Kalaris Therapeutics, Inc. Common Stock's free cash flow?
- After $36.5K of capital expenditures, Kalaris Therapeutics, Inc. Common Stock's free cash flow was -$86.8M over the trailing twelve months.
- Where does Kalaris Therapeutics, Inc. Common Stock's cash flow data come from?
- Every line is extracted from Kalaris Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.